MinorAntiplatelet agents – P2Y12 receptor inhibitors×Proton pump inhibitors
Updated · Methodology
Mechanism
Clopidogrel is a prodrug that needs CYP2C19 for activation, and its label lists the inhibitors to avoid: omeprazole and esomeprazole, fluvoxamine, fluoxetine, moclobemide, voriconazole, fluconazole, ticlopidine, carbamazepine and efavirenz. Pantoprazole is not on that list, which is why it serves as the compatible PPI when the stomach needs protection without losing antiplatelet effect.
Symptoms
The combination produces no symptoms of its own. What is watched is bleeding from the antiplatelet itself: black stools, bruising, gum bleeding. A long PPI course adds hypomagnesaemia and lower vitamin B12, unrelated to clopidogrel.
Management
If a patient on clopidogrel needs a proton pump inhibitor, pantoprazole is suitable: the clopidogrel SmPC approved by the European Medicines Agency (EMA) states that clopidogrel can be given with pantoprazole, and the pantoprazole label approved by the US Food and Drug Administration (FDA) requires no clopidogrel dose change. Omeprazole and esomeprazole are avoided with clopidogrel (clopidogrel SmPC, EMA; clopidogrel label, FDA).
Check the full regimen, not just this pair
Opens the checker with these two drugs prefilled. Add the rest of the regimen and recompute additive risks.
Summary of a multi-drug list →
Medicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica Clopidogrel Cinfamed 75 mg comprimidos recubiertos con película EFG (2023)– AEMPS, CIMA, nº registro 71622, secciones 4.4 y 4.5
- AEMPS: Ficha técnica Pantoprazol Cinfa 40 mg comprimidos gastrorresistentes EFG (2021)– AEMPS, CIMA, nº registro 68076, sección 4.5
- EMA: Ficha técnica: Clopidogrel (EU/1/98/069), sección 4.5 (2022)– EMA, Plavix 75 mg, EU/1/98/069, revisión 12/2022, CIMA nº registro 98069001, sección 4.5
- FDA: Protonix (pantoprazole) prescribing information (2026)– FDA, DailyMed setid 08098cb2-c048-4640-f387-6beec4a38936, revised 05/2026, sections 7 and 12.3
- FDA: Plavix (clopidogrel) prescribing information (2025)– FDA, DailyMed setid de8b0b67-eb25-4684-83b5-7ad785314227 (Sanofi-Aventis U.S.), revised 05/2025, sections 5.2 and 7.4